DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension.

Respir Physiol Neurobiol

Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalier Universitaire de St-Etienne, Faculté de Médecine de Saint Etienne, France; INSERM CIC 1408, Centre Hospitalier Universitaire de St-Etienne, Saint-Etienne, France; INSERM SAINBIOSE UMR1059, équipe DVH, France.

Published: August 2020

The ratio of the diffusing capacity of the lung for carbon monoxide (DLCO) and for nitric oxide (DLNO) measured simultaneously is modified in patients with precapillary pulmonary hypertension (PH). The potential impact of targeted therapy on the DLCO/DLNO ratio is unknown. Simultaneous measurements of DLNO and DLCO were performed at baseline, 3-4 month follow-up (first evaluation) and 12-month follow-up (second evaluation) after initiation of targeted PH therapies in incident cases of precapillary PH. The main outcome was the change in DLNO/DLCO ratio under treatment between baseline and the first evaluation. Twenty-nine patients were included (mean age: 66.8 years, 62.1% female). No significant change in the DLNO/DLCO ratio was found between baseline and the first evaluation. Similarly, no significant differences were noted with regard to changes in Dm or Vc, the DLNO/DLCO ratio in different patient subgroups, or in the 20 patients evaluated at the second follow-up. Within the limitations of this study, the DLNO/DLCO ratio is not useful in monitoring the response to treatment in PH.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.resp.2020.103467DOI Listing

Publication Analysis

Top Keywords

dlno/dlco ratio
20
targeted therapy
8
pulmonary hypertension
8
change dlno/dlco
8
baseline evaluation
8
ratio
6
dlno/dlco
5
ratio evolution
4
evolution targeted
4
patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!